Resectable Pancreatic Cancer clinical trials

Explore recruiting resectable pancreatic cancer clinical trials.

Recruiting resectable pancreatic cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Resectable Pancreatic Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study

Netherlands, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase I/II trial of peri- and postoperative treatment with histamine dihydrocloride and low-dose interleukin-2 in patients with primary resectable pancreatic cancer.

Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A national randomised multi-centre phase II/III trial using MesoPher in ABC borderline resectable pancreatic cancer (PREOPANC-6 trial)

Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

Neoadjuvant Triple Treatment with mFOLFIRINOX, pembrolizumab and SABR in patients with (borderline) resectable pancreatic cancer (PREOPANC-5): a multicenter single arm phase Ib/II trial of the Dutch Pancreatic Cancer Group

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Using organoids to predict efficacy of adjuvant treatment to improve outcome in resectable pancreatic cancer (UNITEPANC)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Resectable Pancreatic Cancer trials by city

Resectable Pancreatic Cancer in Toronto Resectable Pancreatic Cancer in Vancouver Resectable Pancreatic Cancer in Montreal Resectable Pancreatic Cancer in Calgary Resectable Pancreatic Cancer in Edmonton Resectable Pancreatic Cancer in Ottawa Resectable Pancreatic Cancer in Winnipeg Resectable Pancreatic Cancer in Quebec City Resectable Pancreatic Cancer in Hamilton Resectable Pancreatic Cancer in Kitchener Resectable Pancreatic Cancer in London Resectable Pancreatic Cancer in Halifax Resectable Pancreatic Cancer in New York Resectable Pancreatic Cancer in Los Angeles Resectable Pancreatic Cancer in Chicago Resectable Pancreatic Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease